Latest Headlines

Latest Headlines

WuXi AppTec says SynTheAll Changzhou facility out of the gate

Shanghai-based WuXi AppTec said its Shanghai SynTheAll Pharmaceutical's Changzhou facility started initial operations in February, showcasing manufacturing and clinical prowess and speed that can attract investors in China and abroad.

China FDA prioritizes innovative drugs as 2015 approvals dipped

China FDA said it plans to get more innovative new drugs approved faster by identifying clear clinical need as a priority even as the number of approvals dipped last year.

Indian drug firms bought big in 2015 M&A; with U.S. manufacturing focus

India-based drug companies spent $1.5 billion to buy U.S. firms in 2015 as part of an M&A; effort focused on securing manufacturing facilities abroad as troubles at home mounted with a deluge of U.S. FDA actions that shut exports. 

Drug manufacturing quality standards push on in India

Foreign regulators and domestic producers in India are stepping into the breach to help the country improve its quality-control standards that have been the target in recent months of warning letters and outright bans for manufacturing shortfalls and in some cases fraud.

India's Lupin remains keen on emerging markets, M&A;

Mumbai-based drugmaker Lupin Pharmaceuticals is not going to let currency fluctuations stand in the way of its growth plans for emerging markets and remains committed to acquiring specialty products for growth in the future, according to a report in the Business Standard.

Indian multinational Cipla secures $550M acquisition of two U.S. firms

Indian pharmaceutical multinational Cipla's U.K. arm, Cipla (EU) Limited, acquired U.S.-based InvaGen Pharmaceuticals and Exelan Pharmaceuticals.

S. Africa hauls up India's Ranbaxy over bacteria found in folic acid tablets

Indian drug manufacturer Ranbaxy Laboratories was warned and asked to account by the South African government after finding a potentially harmful active ingredient in folic acid tablets sold by the company.

Athenex details $225M China-New York drug manufacturing play

An investment of $225 million will see China investor-backed Athenex make active pharmaceutical ingredients (APIs) and oncology in western New York state and ship products to China and the world.

India aims to detail new policies next month to boost bulk drug output

India's government plans to release the country's new policy on bulk drugs in a month, Minister of State Ministry of Chemicals and Fertilizers Hansraj Ahir said during Mumbai's weeklong Make in India event.

GSK plans $73M upgrade to Nashik plant in India

GlaxoSmithKline plans to invest INR500 million ($73 million) in an upgrade of its manufacturing plant in Nashik northeast of the India financial capital Mumbai to build up output of thyroid and dermatology products, the Business Standard reports.